Traws Pharma (TRAW) Director Jack E. Stover Receives Award

What Happened

• Jack E. Stover, a director of Traws Pharma, was granted a derivative award of 14,150 stock options on July 9, 2026. The Form 4 records the acquisition price as $0.00 (award/grant), i.e., this is an equity compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-09; Filing date (Form 4): 2026-07-14 (appears filed after the typical 2-business-day deadline).
• Instrument and amount: 14,150 stock options (derivative award) recorded at $0.00.
• Vesting: Per footnote, the options vest 100% on the first anniversary of the grant date (i.e., one-year cliff).
• Plan: Award granted under the Issuer's 2021 Incentive Compensation Plan, as amended; compensation committee (independent directors) approved the award.
• Shares owned after transaction: Not specified in the provided filing.

Context

• This transaction is a compensation grant (not an exercise or sale). Such awards are common for directors and do not represent an immediate cash investment or disposal of shares. Because the options vest in one year, they are not immediately exercisable/sellable until vesting occurs. The Form 4 filing date suggests the report was submitted after the typical 2-business-day reporting window.